MitraClip Procedure Can Be Performed without General Anesthesia

Courtesy of Dr. Carlos Fava.

Avoiding general anesthesia in intervention procedures has the benefits of faster recovery and shorter hospitalization. This has been already analyzed in the context of TAVR, but not in MitraClip procedures.

Es posible realizar MitraClip sin anestesia general

The present study analyzed 232 patients receiving the MitraClip. 76 of these procedures were done under general anesthesia (32.7%) and 156 under deep sedation (67.3%).


Read also: The SOURCE 3 Confirms the Good Outcomes of the SAPIEN 3 at One Year Followup”.


Populations were similar in age, comorbidities, EuroScore, severity of mitral failure, left and right ventricular function, and renal function.

 

Both strategies saw safe MitraClip implantation, with no difference in number of implanted clips, or residual mitral failure (with low complications rate). Only 2 patients required conversion to general anesthesia. Total procedural time was lower with deep sedation (DS), driven mainly by preparation.

 

Intensive care was shorter with DS (2.6±4.4 vs. 1.5±1.4 p=0.003). However, hospital stay was similar.


Read also: New Study Confirms TAVR Durability at 5 Years”.


At 90 day follow up, both groups improved functional class and quality of life, saw reduced systolic pressure and BNP.

 

Conclusion

MitraClip implantation with DS is as safe and effective as with general anesthesia.

 

Commentary

Simplifying endovascular procedures with no quality compromise has always been beneficial.

 

Performing MitraClip procedures without general anesthesia reduced intensive care days, but with no difference in overall hospital stay. This might be because the researchers looked at patients between 2011 and 2015. After gaining experience and improving devices, this factor might improve as well. 

 

To know the kind of patients that will benefit from this strategy calls for further research.

 

Courtesy of Dr. Carlos Fava.

 

Original Title: Deep Sedation Vs. Geneal Anesthesia in 232 patients undergoing Percutaneous Mitral Valve repair using the MitraClip® System.

Reference: Patrick Horn, et al Catheterization Cardiovascular Intervention 2017 Published online.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....